So, be patient, and youll see the results
For regulators and payers, interdependence-aware attribution offers a complementary tool for evaluating RWE-based claims
Efinopegdutide is another GLP-1R and GCGR dual agonist currently under clinical investigation, which is being explored in studies for patients with obesity, type 2 diabetes (T2D), and metabolically associated fatty liver disease/multiple acyl-CoA dehydrogenase deficiency syndrome (MASLD/MASH)
Additionally, the efficacy of pro-motility agents, such as metoclopramide and erythromycin, in accelerating gastric emptying in these patients should be explored in future studies [42]
Dehydration risk is also higher in older adults, which amplifies the kidney safety advantage of tirzepatide (lower AKI reporting rate)